Login to Your Account



Genoa seeks 'breath of fresh air' in IPF with inhaled pirfenidone

By Marie Powers
Staff Writer

Monday, July 7, 2014
Mark Surber, president and CEO of Genoa Pharmaceuticals Inc., has witnessed firsthand the devastation wrought by idiopathic pulmonary fibrosis (IPF), a lung disease linked both to genetic and environmental factors that results in progressive lung scarring. Surber's father and grandfather both died from the disease, and other family members are susceptible.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription